Mohan V, John M, Baruah M, Bhansali A
J Assoc Physicians India. 2014 Jan;62(1 Suppl):10-4.
Diabetes has reached epidemic proportions worldwide. It is a major health hazard particularly in developing countries like India due to the genetic susceptibility and changes in lifestyle. Glycaemic control is very poor in India as reflected by recent studies showing average HbA1c of > 9%. Insulin therapy is the mainstay of diabetes management. Currently available insulins have certain limitations. Modern insulin therapy needs to overcome these limitations to effectively achieve the optimal glycemic control. Hypoglycaemia is one of the important barrier which limits the use of insulin therapy and incidence of hypoglycaemia increases with increased variability in glucose lowering effects of Insulin when one tries to achieve stricter glycaemic targets. Fixed time administration is another important barrier, particularly for basal insulin administration that may affect the quality of life. Also the available basal insulins do not provide complete 24 hours control of fasting hyperglycaemia. Insulin degludec is designed to have a flat and stable glucose-lowering effect for more than 42 hours with less risk of hypoglycaemia. And it overcomes most of the issues with currently available basal insulins.
糖尿病在全球已达到流行程度。它是一个主要的健康危害，特别是在像印度这样的发展中国家，这是由于遗传易感性和生活方式的改变。近期研究表明印度的血糖控制非常差，平均糖化血红蛋白（HbA1c）>9%。胰岛素治疗是糖尿病管理的主要手段。目前可用的胰岛素有一定局限性。现代胰岛素治疗需要克服这些局限性以有效实现最佳血糖控制。低血糖是限制胰岛素治疗使用的重要障碍之一，当试图实现更严格的血糖目标时，随着胰岛素降血糖效果变异性增加，低血糖发生率也会增加。固定时间给药是另一个重要障碍，特别是对于基础胰岛素给药，这可能会影响生活质量。而且现有的基础胰岛素不能完全控制24小时空腹高血糖。德谷胰岛素的设计目的是具有超过42小时的平稳、稳定降血糖作用，且低血糖风险较低。它克服了目前可用基础胰岛素的大多数问题。
